Abstract Background Standardised management protocols of paediatric Crohn's disease (CD) are lacking in Israel, leading to a wide heterogeneity of care across paediatric centres. In this quality improvement Programme, named QPID, we aimed to construct a population-based non-research platform that records clinically important quality indicators of CD in all paediatric IBD centres in Israel, to improve treatment outcomes across the country. Methods Representative of all 20 paediatric IBD centres in Israel formed part of a Delphi group to select quality indicators for the QPID (including process and outcome indicators). Eligibility criteria for this program were children with CD seen in clinic, age 2–18 years, not recorded in during the previous 2 months. Children with disease duration <3 months were excluded and a cap of 20 patients per month per site avoided dominance effect of large centres. The indicators were recorded on a REDCap eCRF platform, managed at a data coordinating centre (DCC). Global assessment of longitudinal disease activity and medications were captured to account for patient-mix at each centre. Centres were coded and their allocation was concealed from all involved parties. Monthly reports were distributed, comparing the performance of the specific centre with previous months and other blinded centres. Results The indicators of 1657 visits were recorded from 09/2017 to 08/2018 (mean children age 14.5 ± 2.9 years; median disease duration 1.92 years (IQR 0.92–3.42)). The majority of visits reported quiescent longitudinal global assessment (55%), 30% reported mild activity, and 15% reported moderate–severe activity. On average, 66% of children were treated with biologics with increasing rates over the year (65% to 70%; p = 0.047) (figure) QPID Quality Indices https://planner.smart-abstract.com/ecco2019/submission/en/abstract/12600/image/add.html . A slight increase in measures indicating mucosal healing was note, from 53% to 64% among those with disease duration of at least 1 year (p = 0.001; figure). Clinical remission rate was stable at 72%. Use of steroids was <5% of all reports reflecting the wide use of nutritional therapy in Israel. Conclusions Quality improvement programs at a country level may be implemented with limited resources while facilitating a national standardisation of care. No causal relationship can be elucidated between the program and the observed improved endpoints. Nonetheless, providing anonymous comparisons with other centres may increase awareness and motivation to improve quality indicators.